US FDA approves Revolution Medicines' pancreatic cancer drug
- On Aug 26, The FDA approved Rasonque, a new drug from Revolution Medicines for adults with advanced pancreatic cancer who have received prior treatment.
- Designed as a once-daily pill, Rasonque functions by blocking several forms of the RAS protein, which drives tumor growth in pancreatic cancer.
- Data from a study of 500 adults showed the drug improved median overall survival to 13.2 months, compared with 6.7 months on standard chemotherapy.
- Andrew Ko, a medical oncologist at the University of California, San Francisco, called it "the biggest development we've had in pancreas cancer in decades."
- Revolution did not immediately respond to a request from Reuters for comment on the drug's pricing and availability following the regulatory clearance.
141 Articles
141 Articles
Developed by the American start-up Revolution Medicines, this medicine is called Rasonque and can be taken as tablets.
FDA approves once-daily pill for deadly cancer after patients' survival rates nearly double
The U.S. Food and Drug Administration approved the use of a new cancer treatment pill Wednesday.Rasonque, manufactured by Revolution Medicines in California, is an inhibitor for the most common type of pancreatic cancer. The tablet, which is taken once daily, targets multiple forms of a protein called RAS that drives tumor growth.In a press release, the FDA called Rasonque a "new treatment option for patients with advanced pancreatic cancer," no…
The U.S. Drug Agency (FDA) has approved treatment for patients with an aggressive form of this cancer, one of the most deadly. In its clinical trial, half of the patients who took it survived more than 13 months, twice as long as that of the chemotherapy group. - Pancreatic cancer: the United States approves promising treatment (Health and well-being).
Coverage Details
Bias Distribution
- 64% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
